Ironwood Pharmaceuticals Inc., of Cambridge, Mass., said top-line data from an exploratory, 93-patient phase IIa trial indicated that IW-3718, a gastric retentive formulation of a bile acid sequestrant, improved heartburn and certain other symptoms associated with refractory gastroesophageal reflux disease (GERD).